ArticleBMC infectious diseases2025
Corynebacterium amycolatum: an underestimated pathogen in early-onset neonatal sepsis-a case report.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiac Tamponade in Late Pregnancy Caused byJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset neonatal sepsis (EOS) is a critical condition primarily caused by maternal-fetal transmission of bacterial pathogens during delivery, with Escherichia coli and Group B Streptococcus being the most prevalent. However, neonatal sepsis can also involve other rare bacteria, including Corynebacterium amycolatum, which was first described in 1988 and is widely recognized as an emerging pathogen in infectious diseases. CASE PRESENTATION: A male infant was admitted to the neonatal intensive care unit (NICU) due to premature birth and tachypnea. His mother had experienced premature rupture of membranes (PROM) 20 days prior. The infant's procalcitonin (PCT) level was significantly elevated, reaching 1.51 ng/ml. Chest X-ray revealed increased and blurred lung markings, slightly decreased lung transparency in both lung fields, with scattered ground-glass opacities, and a few fine granular shadows. Corynebacterium amycolatum was isolated from the blood cultures and identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) with 99.9% confidence. Antimicrobial susceptibility testing showed that the isolate was sensitive to penicillin, cephalosporins, and vancomycin, yet resistant to ciprofloxacin, clindamycin, and erythromycin. Empirical treatment with ampicillin and cefoperazone/sulbactam was initially started. Followed by ceftazidime based on susceptibility results, the infant's condition significantly improved, leading to discharge.
conclusionThis case emphasizes the importance of recognizing C. amycolatum as a potential pathogen in neonatal sepsis, especially in preterm infants, and underscores the necessity of accurate identification methods such as MALDI-TOF MS to avoid misidentification. Given the severe clinical outcomes associated with this condition, heightened awareness and diagnostic precision are crucial for optimizing treatment strategies in neonatal intensive care units. This report highlights a rare case of EOS caused by C. amycolatum in a premature infant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.